×

Tetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ICAAC/ICC 2015

WATERTOWN, Mass., Aug. 25, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that 11 data presentations at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting will feature the company's lead drug candidate, eravacycline, as well as its preclinical pipeline program for TP-271. ICAAC/ICC 2015 will take place September 17 to 21 in San Diego, California.

The details for the data presentations at ICAAC/ICC 2015 are as follows:

Eravacycline poster presentations:

Presentation Title: Assessment of Eravacycline Against Recent Gastro-Intestinal (GI) and Genito-Urinary (GU) Clinical Isolates Collected During 2013-2014
Poster Number: C-094
Date and Time: Friday, September 18 from 12:00 pm – 2:00 pm PDT
Location: Exhibit Hall F
Session Title: Clinical Epidemiology of Antimicrobial Resistant Pathogens

Presentation Title: Assessment of Eravacycline Against Non-fermenting Gram-negative Clinical Isolates Isolated in 2013-2014
Poster Number: C-095
Date and Time: Friday, September 18 from 12:00 pm – 2:00 pm PDT
Location: Exhibit Hall F
Session Title: Clinical Epidemiology of Antimicrobial Resistant Pathogens

Presentation Title: Activity of Eravacycline against Carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii
Poster Number: F-769
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: Protein Synthesis Inhibitors

Presentation Title: Activity of Eravacycline and Comparators Against 3,174 Pathogens Isolated from Canadian Hospitals: CANWARD 2014
Poster Number: F-771
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: Protein Synthesis Inhibitors

Presentation Title: Activity of Eravacycline against E. coli Clinical Isolates from U.S. Veterans (2011) in Relation to Co-resistance Phenotype and Sequence Type 131 Status
Poster Number: C-624
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: New Drugs against Gram-Negatives: In Vitro Activity and Insights

Presentation Title: Assessment of Eravacycline Against a Recent Global Collection of 4,462 Enterobacteriaceae Clinical Isolates (2013-2014)
Poster Number: C-619
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: New Drugs against Gram-Negatives: In Vitro Activity and Insights

Presentation Title: Assessment of Eravacycline Against 3,467 Recent Gram-positive Bacteria, Including Multidrug-resistant Isolates Collected from 2013-2014
Poster Number: C-563
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: In vitro Activities of New Drugs and Inhibitors against Gram-Positives

Presentation Title: In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates
Poster Number: C-547
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: In vitro Activities of New Drugs and Inhibitors against Gram-Positives

Presentation Title: Effect of Renal Function on Efficacy in IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline versus Ertapenem in Complicated Intra-Abdominal Infections
Poster Number: L-835
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: Gastrointestinal Tract Infections

Presentation Title: Results in Higher-risk Subgroups From IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline versus Ertapenem in Complicated Intra-abdominal Infections
Poster Number: L-834
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: Gastrointestinal Tract Infections

Pipeline program poster presentations:

Presentation Title: TP-271, a Novel Fluorocycline, is Efficacious in Post-exposure Prophylaxis (PEP) and Treatment (Tx) Models of Aerosolized Bacillus anthrax (Ba) Infection in BALB/c Mice
Poster Number: F-768
Date and Time: Saturday, September 19 from 11:00 am – 1:00 pm PDT
Location: Exhibit Hall F
Session Title: Protein Synthesis Inhibitors

Full abstracts can be found on the ICAAC website at http://www.icaac.org/.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). This program includes two phase 3 clinical trials: IGNITE1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE2 for the indication of complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. In addition to eravacycline, Tetraphase's pipeline includes two preclinical antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.

Forward-Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether results obtained in preclinical studies and early or interim clinical trials will be indicative of results obtained in future clinical trials; whether eravacycline will advance through the clinical trial process on a timely basis; whether the results of the Company's trials will warrant regulatory submission and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if eravacycline obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on August 6, 2015. In addition, the forward-looking statements included in this press release represent our views as of August 25, 2015. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

CONTACT: Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 tdahlman@tphase.com Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 mikebeyer@sambrown.com Argot Partners Susan Kim 212-600-1902 susan@argotpartners.com

Source:Tetraphase Pharmaceuticals